English
Język Polski
Adaptability of clinical pharmacist led interventions in the management of anemia of chronic renal disease: optimizing care
Girish B S
Srinivasan R
Joel M. Johns
C S Meghana
Abstrakt
Renal anemia is a common comorbidity in chronic kidney disease (CKD) patients, typically treated with erythropoiesis-stimulating agents (ESAs) like erythropoietin. However, both over- and under-treatment are prevalent. In 2008, the Pharmacy Council of India introduced the Pharm.D course to enhance pharmaceutical care in clinical settings. While extensive studies in other countries highlight the benefits of clinical pharmacists' interventions, Indian research on this topic is limited. This prospective randomized controlled trial included CKD patients not on dialysis, with serum creatinine levels of 2-6 mg/dL and hemoglobin (Hb) levels below 12 g/dL. Participants were divided into three subgroups based on baseline Hb levels: < 10 g/dL (Group I), 10-12 g/dL (Group II), and >12 g/dL (Group III). ESAs and iron supplements were adjusted to maintain Hb levels of 10-12 g/dL. Quality of life was assessed using the Short Form Health Survey-36 questionnaire. Out of 448 participants, those in the pharmacist intervention group showed a significant shift towards Group II by the trial's end, compared to the control group. The study demonstrated a significant improvement in quality of life and physical performance, particularly for those in Group II, indicating that maintaining Hb levels at 10-12 g/dL is optimal for Indian CKD patients. This trial exemplifies the profound impact clinical pharmacists can have on patient care, highlighting their crucial role in improving healthcare outcomes through active participation and targeted interventions in clinical settings.
Podobne artykuły
- Karolina Księżarczyk, Bartłomiej Sankowski, WYBRANE ASPEKTY ŻYWIENIA POZAJELITOWEGO , Prospects in Pharmaceutical Sciences: Tom 15 Nr 4 (2017)
- Bartosz Kózka, Anna Kowalkowska, POCHODNE BENZIMIDAZOLU WYKAZUJĄCE AKTYWNOŚĆ BIOLOGICZNĄ , Prospects in Pharmaceutical Sciences: Tom 15 Nr 3 (2017)
- Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula, The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients , Prospects in Pharmaceutical Sciences: Tom 21 Nr 1 (2023)
- Olga Grelewicz, Gabriela Kulbacka, Tomasz Mikuła, Alicja Wiercińska-Drapało, Does testosterone intake affect diagnosing primary HIV infection? , Prospects in Pharmaceutical Sciences: Tom 21 Nr 1 (2023)
- Teresa Żołek, Aleksandra Trzeciak, MECHANIZM DZIAŁANIA INDOLO-3-KARBINOLU I 3,3´-DIINDOLILOMETANU W CHEMOPREWENCJI CHORÓB NOWOTWOROWYCH , Prospects in Pharmaceutical Sciences: Tom 15 Nr 2 (2017)
- Dibyajyoti Saha, Satish Kumar Sarankar, Critical review on potentials of ethnopharmacological, ethnomedicinal and traditional practices of Madhuca longifolia (J. Koenig Ex L.) J. F. Macbr. (Family: Sapotaceae) , Prospects in Pharmaceutical Sciences: Tom 21 Nr 2 (2023)
- Mustafa Sevindik, Falah Saleh Mohammed, Imran Uysal, Autism: plants with neuro-psychopharmacotherapeutic potential , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
- Elżbieta Gniazdowska, Edyta Gilant, Katarzyna Buś-Kwaśnik, ICH M10 guideline - a harmonized global approach to bioanalysis , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
- Seda Sultan Sağır, Baturay Sapancı, Imran Uysal, Mustafa Sevindik, A review: nutrition and oral-dental health, phytochemical content, biological activity of Salvadora persica (Miswak) , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
- Adam Piasecki, Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison , Prospects in Pharmaceutical Sciences: Tom 20 Nr 1 (2022)
Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.
Szczegóły
Bibliografia
Statystyki
Autorzy
Zasady cytowania
Cited by / Share
Licencja
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.